spacer
home > epc > spring 2009 > oncology: biomarkers promise progress
PUBLICATIONS
European Pharmaceutical Contractor

Oncology: Biomarkers Promise Progress

The discovery and development of novel drugs remains a process fraught with high attrition rates and many technological, scientific and financial challenges. The cost to bring a new drug to market is estimated at $800 million and is predicted to increase 7.4 per cent above inflation on an annual basis (1). Over 75 per cent of these costs are expended on unsuccessful compounds and, in spite of billions spent on preclinical and clinical studies, post-launch withdrawal of compounds due to adverse side effects still occurs. Opportunities for the pharmaceutical industry lie in the integration of discovery and development functions to bring affordable, effective and safe drugs to patients. Many drug candidates still fail in clinical studies because we cannot accurately predict how effective or how safe these candidates will be in humans based solely on animal studies. Knowing the pharmacokinetics and pharmacodynamics of a drug candidate and the response of a patient to therapeutic intervention is crucial to successfully designing effective clinical trials. Biomarker technologies that are able to increase understanding of a drug’s mechanism of action at an early stage, precise dosing, and a regime of administration will generate valuable information on the drugs activity and accelerate the drug development process (2).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Lydia Meyer-Turkson is Director of the Biomarker Division at Epistem Ltd. She has a BSc honours and MPhil postgraduate degree in Chemistry from University College Cardiff and received an MBA from Manchester Business School. She has over 15 years business development experience in the contract research sector, setting up drug discovery and development collaborations between biotech and pharmaceutical companies across Europe and the US. She recently joined Epistem from a role as VP Business Development at Evotec AG.

spacer
Lydia Meyer-Turkson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera acquires Insight Product Development to strengthen its capabilities

“Every day at Nemera, we work to improve the lives of millions of patients worldwide by designing, developing and manufacturing innovative drug delivery devices. Our vision as a team is to become the most patient-centric drug delivery device company in the industry. We partner closely with our customers to deliver innovative and high quality devices, to ensure that patients will receive the best product and service possible” Marc Hämel, CEO
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement